Company Intro: Stylam started in 1991 and is the fastest growing laminate company and has diverse product portfolio. Company has has the manufacturing facilities for Solid Acrylic Surfaces and Panels
Laminate manufacturing capacity is 14.3 mns sheet and spreaded across 44 acres
β’ Product portfolio includes around 20 major products
β’ Creditors levels remains less than 1 month since 2013
β’ Export: Good order book in hand and mainly it was export driven.
Domestic: Domestic Demand decreased due to COIVD. However festive season is picking the demand.
Gross Margins: Raw material prices were down.
And as turnover increases cost of manufacturing decreasing leading to increase in margin.
COVID- Maximum sales in Europe. However nothing much impact have been seen due to COVID, and the October order remained at same Level
Customer segment:
- Retail side the company is facing less problem.
- Institutional based the company is facing problem.
β’ Competition from unorganized share is strict.
β’ Phenol prices decline is 46%.
Laminate Segment: 30% incremental production can easily be made with the available capacity.
Acrylic Surface: Not losing any money from acrylic surface though they are manufacturing capacity is still at negligible stage.
Total turnover expected from acrylic is 200 crores
Capacity Expansion:
β’ There is no expansion plan in the near future. Already done the Phase 2 to expansion
β’ Maintenance CAPEX would be less than depreciation.
β’ Already have enough land to expand for the coming two year. Hence no need for any CAPEX.
β’ Reduction in raw material, installed a machine one month before lockdown to increase production in lamination.
β’ Increase in margins due to raw material and fixed product.
Advertisement:
β’ Advertisement to restart from January to gain the domestic market
β’ Around 1-2% of sales will be Advertisement expense would be continuous spend.
β’ Sponsored IPL in team of Kings XI Punjab luckily which is performing good this year.
β’ Distributor is 150 right now and it will be increasing.
β’ Company has also started digital marketing
β’ Currently on operational scale there is problem since last one month, however it will be cleared now.
Diversification in IT: Company just expanded in IT, as many other companies were diversifying. However that was blunder. It was due to suggestion from management kids. But was company realized the mistake and sold the segment sooner.
Updates:
β’ Strong recovery in branded generic market
β’ Doctor spending time in clinic increase
β’ Growth in Chronic segment improved
β’ Share of Chronic and sub chronic in 77% which was 71% in last year same quarter
β’ Company is Continue to gain market share in cardio vascular space.
β’ Company is trying reducing focus on tender business. Other from tender business has seen 10% growth.
β’ In Q3 company launching new brands.
β’ US growth was impacted due to price erosion , and other factors
- Revenue and exports grew more then 20%
- 55% of the growth was mainly due to volume in API
- API contributed 88% and formulations 12%
- Under API 56.17% revenue came from export
- Company maintained efficiencies and costs
- D/E reduced due to strong internal accrual
- Good growth in formation exports
- Scaled up anti-inflammatory capacities
- Working on backward integration and API capex
Updates:
β’ Key focus will be now brand recognition.
β’ Now co. has low concern of labour.
β’ Tier 1 and Tier 2 see health double digit growth.
β’ Sequential basis saw good recovery after COVID.
β’ Quarter 2 had saw New infra investments.
β’ Metro, Power, Infra are also starting working fast, hence kicked on new quarter with positive note.
β’ B2B wire and cable saw on recovery
β’ Company has be continue participating in TV Media.
β’ Finance cost lowered by 14%
β’ Other income was mainly due to forex gain
Updates:
β’ Large account of sales this time gave profitability
β’ Power and fuel cost were in line
β’ Further margins to improve because of new electricity plant at Gujarat
β’ In terms of export and proprietary business, planned strategy is fully getting implemented
β’ Order on hand: At around 350 crores. As this order gets shipped, management feels to get more profitability in terms of margins.
β’ Pharma and chemical sector are looking very very strong
β’ Most of the demand from pharma and chemical is new demand.